Amarin Corp Plc — informes financieros trimestrales (NASDAQ:AMRN)

Ver el calendario completo

Financials

Visión general Informes Estadísticas

Trimestre Año

Market Capitalization 295.4162 M
Employee 80
Founded 1989
CEO N/A
Website www.amarincorp.com
Headquarter United Kingdom
FIGI BBG000BPYG99
Industry Fabricantes de medicamentos — general

Ingresos totales

Beneficio neto

Beneficio básico por acción

Deuda total

Flujo de caja libre

Efectivo y equivalentes

295.42 M Capitalización de mercado

Ratio precio/beneficio

-155.06

Relación precio/flujo de caja

27.11

Amarin Corporation plc - American Depositary Shares, each repre

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa, a prescription grade omega-3 fatty acid. In July 2012, their lead-candidate drug named Vascepa received FDA-approval, competing against GlaxoSmithKline's Lovaza.

AMRN

Financials

Amarin Corporation plc - American Depositary Shares, each repre

Noticias

ABBV Seeks FDA Nod for Rinvoq Label Expansion in Alopecia Areata

Novartis Q1 Earnings & Revenues Miss Estimates, Stock Down

AbbVie's TrenibotE Receives FDA CRL Due to Manufacturing Issues

Has Amarin (AMRN) Outpaced Other Medical Stocks This Year?

AMRX Announces Kashiv BioSciences Buyout, Solid Q1 Preliminary Results

MRK Down as Triplet Therapy Fails to Meet Goal in Kidney Cancer Study

MRK Down as Triplet Therapy Fails to Meet Goal in Kidney Cancer Study

MRK's sBLAs for Keytruda Combo in Bladder Cancer Get FDA Priority Tag

BIIB Inks Deal to Acquire Rights to Felzartamab in China, Stock Up

Merck to Boost Oncology Pipeline With $6.7B Terns Buyout, Stock Up

Amarin presentará datos de subgrupos de REDUCE-IT en congreso de cardiología

Amarin to present REDUCE-IT subgroup data at cardiology meeting